Retatrutide vs Tirzepatide vs Semaglutide
Retatrutide, tirzepatide, and semaglutide are incretin-class research peptides studied in metabolic and energy-balance models. They differ chiefly in how many incretin receptors each one engages. This reference summarizes their molecular class and the research contexts in which each is investigated — it is not medical or dosing guidance.
| Aspect | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Receptor targets | GLP-1 · GIP · glucagon (triple agonist) | GLP-1 · GIP (dual agonist) | GLP-1 (mono agonist) |
| Compound class | Synthetic incretin tri-agonist peptide | Synthetic incretin co-agonist peptide | GLP-1 receptor agonist analog |
| Primary research focus | Energy balance & metabolic signaling | Glucose-handling & metabolic models | Appetite & glucoregulatory pathways |
| Format | Lyophilized powder, sealed | Lyophilized powder, sealed | Lyophilized powder, sealed |
| Purity | ≥99% HPLC | ≥99% HPLC | ≥99% HPLC |
Why receptor count matters in the literature
The three compounds are often grouped by how many incretin receptors they activate. Semaglutide is studied as a single-receptor (GLP-1) agonist; tirzepatide adds GIP activity; retatrutide adds glucagon-receptor activity on top of both. Researchers select among them when a model calls for single- versus multi-pathway incretin signaling.
Handling and reconstitution
All three ship as lyophilized powder sealed under nitrogen and are reconstituted with bacteriostatic water for laboratory work. Store lyophilized material cold and protected from light; follow standard peptide-handling practice for your protocol.
Questions
For Research Use Only. Not for human or animal consumption. The above is a neutral summary of compound class and published research context; it is not medical, dosing, or usage guidance, and has not been evaluated by the Food and Drug Administration.